Loading
A phase 3 trial of docetaxel in lung cancer, run by Jemincare, not yet recruiting.
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC is a phase 3, randomised interventional study registered as NCT07242274 by Jemincare, with a registry enrolment figure of 472 participants, started 2025-12-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: JMKX001899; Docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer). Primary outcome: PFS. Lung eligibility wording from the registry: "Histologically or cytologically confirmed NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.